Virta Health focuses on reversing type 2 diabetes through a combination of personalized nutrition, continuous remote care, and behavioral science. Their treatment is designed for individuals diagnosed with type 2 diabetes, healthcare providers, and enterprise partners like employers and health plans. Unlike traditional diabetes management approaches, Virta Health aims to achieve actual reversal of the condition. They operate on a performance-based business model, meaning they only receive payment from enterprise partners if they successfully help patients reverse their diabetes. This aligns their financial success with patient outcomes, encouraging the adoption of their services. Virta Health's goal is to reverse type 2 diabetes in 100 million people, making them distinct in the healthcare market by focusing on long-term health improvements rather than just management of the disease.

Creandum

Obvious Ventures

Venrock

SciFi VC

Founders Fund

Playground Global

Caffeinated Capital

Sequoia

Tiger Global

Redmile Group

Bronze Investments

Max Levchin

PayPal

Allen & Company

Great Oaks Venture Capital

Rock Health

Biotechnology

Healthcare

Virta Health

To help employers, health plans, and pharmacy benefit managers deliver best-in-class outcomes with or without GLP-1 medications, Virta recently launched Responsible Prescribing, an expansion of its SWL suite.

Virta Health Announces Record and Accelerating Growth at a Scale of More Than $100M in Annualized Revenue, Driven by Sustainable Weight Loss and GLP-1 Solutions

Capital Rx's Senior Vice President of Pharmacy, Sara Izadi, PharmD, joined Virta's President, Kevin Kumler, Commercial Health Director, Frank Dumont, MD, FACP, and Chief Medical Officer, Adam Wolfberg, MD, MPH, to provide holistic feedback on the use of GLP-1s for weight loss, rising pressure on health plans to cover this new drug class, and other clinical strategies to address obesity.

Replay: rethinking obesity strategies - the rise of GLP-1 drugs and lifestyle programs for weight loss

Physicians Reveals GLP-1s for Weight Loss are Overprescribed and Unsustainable by Jasmine Pennic 08/06/2024 Leave a Comment  What You Should Know:  – A large majority of physicians feel GLP-1s are being overprescribed, according to a new survey from Virta Health, a leader in type 2 diabetes reversal.  – The Virta Health survey was conducted in partnership with Beresford Research and included 300 primary care providers, endocrinologists, and obesity specialists across the United States sheds light on the medical community’s views on the rapidly growing class of GLP-1 medications, often hailed as “miracle drugs” for weight loss.  Key Findings Reveals Skepticism About Weight Loss Drugs The key findings reveal significant concerns about the long-term efficacy, potential side effects, and overall impact of these medications on public health:  – Doubtful about long-term efficacy: Most physicians believe GLP-1 medications are not sustainable beyond two to three years and should not be used as a long-term solution. – Overprescription concerns: A large majority of physicians feel GLP-1s are being overprescribed and that lifestyle interventions should be prioritized. – Need for stricter guidelines: Physicians advocate for increased oversight through prior authorization and greater provider involvement in prescribing decisions. – Patient misconceptions: Many doctors report that patients have unrealistic expectations about the effectiveness and safety of GLP-1 medications. – Potential for increased healthcare costs: The widespread adoption of GLP-1s is expected to drive up healthcare costs due to increased demand and limited supply. – Concerns about health equity: Physicians are worried about the potential for increased health disparities as GLP-1 medications may not be equally accessible to all patients

Physicians Reveals Glp-1S For Weight Loss Are Overprescribed And Unsustainable

Following GLP-1 deprescription, weight did not significantly increase at 6 or 12 months post deprescription, compared to many well-known drug trials (in red) where patients regain up to 2/3rds of weight loss after discontinuing the drug. (Graphic: Business Wire)Following GLP-1 deprescription, weight did not significantly increase at 6 or 12 months post deprescription, compared to many well-known drug trials (in red) where patients regain up to 2/3rds of weight loss after discontinuing the drug. (Graphic: Business Wire)DENVER--(BUSINESS WIRE)--Virta Health has released first-of-its-kind, peer-reviewed data demonstrating the company’s approach to personalized nutrition therapy results in sustained weight loss after the discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1s), including Ozempic. Published today in Diabetes Therapy, the data demonstrates Virta is a powerful and sustainable off-ramp from GLP-1s.These outcomes stand in stark contrast to other real-world results of GLP-1 weight loss treatments. Discontinuing the medications has been shown to lead to rapid worsening of blood sugar and weight regain, even when accompanied by physical activity and calorie restriction. Additionally, as many as two out of three people on GLP-1s stop within a year and quickly regain the weight they lost, underscoring the need for an effective medication-free alternative and off-ramp from the medications to achieve sustainable results.The study assessed weight loss in two groups of Virta members with type 2 diabetes: those for whom (a) GLP-1s were fully deprescribed and (b) GLP-1s were continued

Virta Health Announces First-Of-Its-Kind Peer-Reviewed Study Proving Its Approach Is An Effective Off-Ramp From Glp-1S For Sustained Weight Loss

DENVER-(BUSINESS WIRE)- Virta Health has released first-of-its-kind, peer-reviewed data demonstrating the company's approach to personalized nutrition therapy results in sustained weight loss after the discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1s), including Ozempic.

Virta Health Announces First-of-its-Kind Peer-Reviewed Study Proving Its Approach Is an Effective Off-Ramp From GLP-1s for Sustained Weight Loss

August 2022 - Reflexion Health acquired HealthySteps, a digital physical therapy provider.

Virtual Rehabilitation and Telerehabilitation Systems Market is expected to witness a CAGR of 19.2% during the forecast period | Coherent Market Insights.

SUNNYVALE, Calif., Aug. 3, 2023 /PRNewswire/ -- Acacia Mental Health ("Acacia"), the leader in rapid, medication-free treatment of depression and anxiety, announced that it has achieved the prestigious Program Validation from Validation Institute for its BRAIN protocol. The Program Validation delivers unmatched cost reductions and better outcomes for treatment-resistant Obsessive Compulsive Disorder (OCD). Per the independent analysis, the BRAIN™ protocol is cost-effective in addressing treatment-resistant obsessive-compulsive disorder, with remission rates >30%. Further, 58% have a meaningful response."It's been remarkable to see people regain hope, when nothing else worked before," says David Carreon, M.D., CEO Tweet this PET Scan Showing biological changes in psychiatric illnessThis validation follows scientific publications co-authored by Acacia scientists. This research showed that remission was possible in many cases

Validation Institute Announces Program Validation Achievement Of Acacia Mental Health

"Its Single-Ledger Model™, coupled with JUDI's capabilities, enables Colorfuldreams to partner with Virta on a solution focused on deprescribing and health equity."

Capital Rx launches Rx Reverse in partnership with Virta Health to combat type 2 Diabetes and Obesity

Health IT veteran Ed Marx announces his departure as CEO at Divurgent to launch his advisory company, Marx Advisory focused on helping healthcare executives  organizations achieve objectives and key results.Particle Health appointed Jason Prestinario as its next CEO, effective today. Troy Bannister, founder and current CEO, will continue with Particle as Chief Strategy Officer, where he will spearhead product innovation.Rhapsody names Jeff Chiumiento as the company’s new chief financial officer to oversee the company’s global financial operations and optimizing business management.Zyter|TruCare™ appoints Jason Cole, as the company’s new executive vice president and chief operating officer.  Cole will report directly to Chief Executive Officer, Kevin Riley, and be responsible for driving enterprise performance overall and deepening the customer and employee-centric operating model.Sana Primary Care appoints virtual primary care pioneer Dr. Jay Parkinson as Chief Medical Officer. Healthcare entrepreneur and physician will lead Sana’s virtual primary care model and its transition to a combined health plan and in-house care delivery model.ModMed® appoints Venkatesh Jayaraman (VJ) as the company’s Chief Technology Officer to lead the strategic direction and technical leadership for the product engineering organization, including cloud operations.MedArrive appoints Peter Samuel, MD (“Rocky”) as Chief Clinical Officer. Dr. Samuel will oversee MedArrive’s home-based clinical programs, help establish clinical protocols and quality standards to ensure strong performance, lead the strategic leadership in developing new use cases and programs, while also spearheading future-forward planning. Virta appoints Dr

Digital Health Exec Hires & Departures: Ed Marx Departure, Others

Major health plans and employers like U-Haul are partnering with Virta for both the clinical results and value-based payment model, where fees are tied to outcomes such as clinically-significant weight loss.

U-Haul, Quartz Health Solutions, and 70+ Other Major Payers Partner with Virta Health to Fight Back Against Obesity Epidemic

Reverses type 2 diabetes through personalized care

Virta Health

Reverses type 2 diabetes through personalized care

Virta Health

Reverses type 2 diabetes through personalized care

About

Simplify's Take

What believers are saying

What critics are saying

What makes Virta Health unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

Virta Health is Hiring for 0 Jobs on Simplify!